Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)
Status:
Active, not recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that treatment with avelumab in combination with
RT-cetuximab is superior to standard of care (SOC) cisplatin-RT and/or to SOC RT-cetuximab
alone in terms of progression-free survival (PFS) in front-line patients with locally
advanced SCCHN.